Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report
Open accessThe DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
Abstract
We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine/z-drugs (BZDRs). Long-term BZDR prescriptions are potentially harmful yet common, partly because of challenging withdrawal symptoms. Few pharmacological interventions have evidence for facilitating BZDR discontinuation, and none in patients actively suffering from TRD. In this ambi-directional cohort study, discontinuation of long-term (>6 month) BZDRs was attempted in 22 patients with severe unipolar or bipolar TRD receiving a course of six subanesthetic ketamine infusions over four weeks. We investigated the rates of successful BZDRs deprescription, trajectories of acute psychological withdrawal symptoms, and subsequent BZDRs abstinence during a mean follow-up of 1 year (primary outcome). Clinically significant deteriorations in depression, anxiety, sleep, and/or suicidality during the acute BZDR discontinuation phase were measured by repeated standardized scales and analyzed by latent growth curve models and percent correct classification analysis. Of the 22 eligible patients, all enrolled in this study and 91% (20/22) successfully discontinued all BZDRs by the end of the 4-week intervention, confirmed by urinary analyses. Less than 25% of discontinuers experienced any significant worsening of anxiety, depression, sleep difficulties, or suicidality during treatment. During follow-up (mean [range] duration, 12 [3–24] months), 64% (14/22) of patients remained abstinent from any BZDRs. These preliminary results suggest that ketamine infusions for TRD may facilitate the deprescription of BZDRs, even in patients with active depressive symptoms and significant comorbidity. Further investigation is warranted into this potential novel application of ketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“very limited evidence was found for use of anesthetics such as ketamine and propofol for facilitating BZD withdrawal.127”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [127]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances, including ketamine infusions, further complicate predictions of long-term outcome, as patients previously regarded as refractory may experience meaningful improvement as novel therapies emerge.21”
From Medical Assistance in Dying for the Sole Underlying Condition of Mental Disorder (MAiD MD-SUMC): an analysis and qualitative evidence synthesis (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following a median observation period of 12 months, 64% of the patients achieved sustained abstinence from BZD/Z-drug use. 92”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [92]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
Jacobson, N. S., & Truax, P. (1991) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.59.1.12 · Cited by 7,770
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965 · cited 1×
“All patients had”
State-Trait Anxiety Inventory for Adults
Spielberger, C. D. (2012) · PsycTESTS Dataset · doi:10.1037/t06496-000 · Cited by 3,479
Assessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Latent Curve Models: A Structural Equation Perspective
Bollen, K. A., & Curran, P. J. (2005) · Wiley Series in Probability and Statistics · doi:10.1002/0471746096 · Cited by 1,729
Psychometric properties of the Beck Depression Inventory-II: a comprehensive review
Wang, Y.-P., & Gorenstein, C. (2013) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2012-1048 · Cited by 1,577
Research works printed but not linked: 1
- Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the state-trait anxiety inventory. Palo Alto, CA, USA: Consulting Psychologists Press; 1983.
Cited by
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“127 Both ketamine and propofol are associated with a significant risk of increased respiratory depression when combined with BZDs, and no evidence supports their use for routine BZD tapering.”
Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 40
Self-citationIngrosso, G., Cleare, A. J., & Juruena, M. F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303597 · Cited by 28
Psychedelics in the Treatment of Substance Use Disorders and Addictive Behaviors: A Scoping Review
Richard, J., & Garcia‐Romeu, A. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00629-8 · Cited by 26
Greenway, K. T., Garel, N., Dinh-Williams, L.-A., Lévesque, J. T., Kaelen, M., Dagenais‐Beaulé, V., de la Salle, S., Erritzøe, D., Looper, K. J., Turecki, G., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.102 · Cited by 16
Self-citation
Metadata
- Authors
- Garel, N., Greenway, K. T., Dinh-Williams, L.-A. L., Thibault-Levesque, J., Jutras-Aswad, D., Turecki, G., Rej, S., & Richard-Devantoy, S.
- Affiliations
- McGill University (CA)
- Jewish General Hospital (CA)
- Douglas Mental Health University Institute (CA)
- Corresponding author
- Garel, Nicolas
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2023-08-02
- Volume
- 48
- Issue
- 12
- Pages
- 1769-1777
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC10579413
- OpenAlex
- W4385482916
- Cited by
- 13
- References
- 65
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 1 · 2023: 1
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- ketamine, treatment-resistant depression, benzodiazepine withdrawal, long-term benzodiazepine use, bipolar depression, withdrawal symptoms, suicidality, anxiety
- MeSH terms
- Deprescriptions, Benzodiazepines, Depression, Humans, Infusions, Intravenous, Ketamine, Substance Withdrawal Syndrome, Cohort Studies, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report. https://app.cochat.ai/papers/10.1038/s41386-023-01689-y
- The paper
- Garel, N., Greenway, K. T., Dinh-Williams, L.-A. L., Thibault-Levesque, J., Jutras-Aswad, D., Turecki, G., Rej, S., & Richard-Devantoy, S. (2023). Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01689-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.